

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)*

**POSITIVE PROFIT ALERT
AND PROPOSED UTILIZATION OF
CAPITAL RESERVE TO OFFSET LOSSES**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSITIVE PROFIT ALERT

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025 (the “**Reporting Period**”) and the information currently available to the Board, the Group is expected to record a net profit attributable to the Shareholders of not less than RMB40 million, representing a significant turnaround from the net loss attributable to the Shareholders of approximately RMB5.1 million for the six months ended June 30, 2024 (the “**Corresponding Period**”). The expected profit and improvement in results is primarily attributable to business growth of the Group resulting in a increase in revenue, as well as a decrease in the overall expense ratio of the Group as compared to the Corresponding Period.

The Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The data and information contained in this announcement is only a preliminary assessment made by the Board based on the consolidated management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company, and are subject to finalization and adjustments. The unaudited interim results of the Group for the Reporting Period, which is expected to be published by the end of August 2025, may differ from the data and information contained in this announcement.

PROPOSED UTILIZATION OF CAPITAL RESERVE TO OFFSET LOSSES

The Board proposes to utilize the Company's capital reserve to offset losses of the Company in accordance with its Articles of Association, relevant laws and regulations. Such offset of losses is subject to the approval by the Shareholders by way of an ordinary resolution, and relevant proposal will be put forward at the 2025 second extraordinary general meeting of the Company to be held on August 29, 2025 for Shareholders' consideration and approval as ordinary resolution. A circular containing details of the proposed offset of losses by utilization of the Company's capital reserve, together with the notice of the meeting, will be despatched to shareholders of the Company in due course.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, July 29, 2025

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.